ImmunityBio shares rose about 3% in pre-market trading after the company reported a breakthrough in manufacturing its natural killer (NK) cell therapy, enabling production of up to 5 billion cells from a single donor. The milestone could support multiple treatment doses and advance its cancer immunotherapy programs.